期刊文献+

维甲酸对乳腺癌细胞MDA-MB453钠碘转运体调控(英文) 被引量:2

Effect of retinoic acid on expression and function of sodium iodide symporter in breast cancer cell
在线阅读 下载PDF
导出
摘要 目的本实验通过维甲酸对乳腺癌细胞的钠碘转运体(NIS)基因及蛋白表达和摄碘功能的影响,探讨乳腺癌细胞NIS的表达特点和调控因素。方法我们采用乳腺癌细胞MDA-MB453进行培养,分别给予不同浓度的维甲酸(RA)进行刺激72h。采用RT-PCR方法检测细胞中NIS的mRNA表达;用WesternBloot方法检测NIS蛋白水平;采用125I测定乳腺癌细胞摄碘功能的变化。结果乳腺癌细胞MDA-MB453在经过RA刺激后,细胞中NIS的mRNA表达比对照组有明显增加,并且与RA浓度成正比。细胞中NIS的蛋白表达比对照组也有明显增加,并且与RA浓度相关。经过RA刺激的乳腺癌细胞摄碘能力明显增加。结论维甲酸对乳腺癌细胞MDA-MB453的NIS基因和蛋白表达均有促进作用,而且促进乳腺癌细胞的摄碘,这提示维甲酸可能通过调节乳腺癌NIS基因和蛋白的表达,从而影响乳腺癌细胞对放射性碘治疗的敏感性。 Objective:To investigate the effect of retionic acid on gene and protein expression of sodium-iodide symporter(NIS)and on the activity of iodide uptake in breast cancer cell(MDA-MB453).Methods:The breast can-cer cell MDA-MB453was cultured with negative control culture or with different concentration of retinoic acid for72hours.NIS gene mRNA in breast cancer cells was determined by reverse transcriptase-polymerase chain reaction(RT-PCR).NIS protein was checked by Western Blot.And the activity of iodide uptake was also assessed.Results:Gene mRNA and protein of sodium iodide symporter could be found increasing along with the concentration of retinoic acid.And augment of the activity of iodide uptake had also been indetified.Conclusion:Retionoic acid may play a role in iodide-uptake modulating in breast cancer cells by the effect on NIS gene and protein expression.
出处 《中国现代医学杂志》 CAS CSCD 2004年第21期11-14,共4页 China Journal of Modern Medicine
基金 Keysubjectfundof"135"projectinJiangsuHealthyOffice.ProjectNumber:2001-3111
关键词 钠碘转运体(NIS) 乳腺癌 维甲酸 sodium iodide symporter breast cancer cell retinoic acid
  • 相关文献

参考文献2

二级参考文献15

  • 1[1]Metcalfe KA,Goel V,Lickley L,et al.Prophylactic bilateral mastectomy:patterns of practice[J].Cancer,2002,95:236-242.
  • 2[2]Mose S,Adanietz IA.Bilateral breast carcinoma versus unilateral disease[J].Sam J Clin Oncol(CCT),1997,20:541-544.
  • 3[3]Karaoglu A,Altundog MK,Erman M,et al.Familial asynchronous bilateral primary male breast carcinoma [J].J Exp Clin Cancer Res,2002,21:143-144.
  • 4[4]Kan X.Clinical pathology of breast cancer[M].Beijing:Press of Xiehe Medical University,1993,98-102.Chinese
  • 5[5]Huang MQ,Wang XH,Jiang SN,et al.Tbe prognostic factor of bilateral primary breast cancer[J].Chin J of Oncol,2002,12:137-140.Chinese
  • 6[6]Huang Y,Song YH,Wei CZ,et al.The clinical character and prognosis of bilateral primary breast cancer[J].Chin J Med,1999,59:691-692.
  • 7[7]Shen ZZ,Liu GY.Think highly of clinical research of pre-cancerous disease of breast cancer[J].Chin J of Apply Surg,2000,20:259-260.Chinese
  • 8Di Leo A, Gancberg D, Larsimont D, et al. Her - 2 amplification and Topoisomerase Ⅱ alpha gene aberrations as predictive markers in node - positive breast cancer patients randomly treated either with an anthracycline - based therapy or with cyclophosphamide, methotrexate, and 5- fluorouracil. Clin Cancer Res, 2002 ;8(5): 1107--1116.
  • 9Trock BJ, Leonesm F, Clarke R, et al. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst, 1997; 89(13):917-931.
  • 10Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase Iialpha associate with ErbB- 2 amplification and affect sensitivity to topoisomerase Ⅱ inhibitor doxorublcin in breast cancer. Am J Pathol, 2000;156(3): 839-847.

共引文献8

同被引文献8

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部